Skin Cancer Committee
Leaders:
Prof. Caroline Robert, Head of the Dermatology
Department; Dr. Émilie Routier, Chair of the Dermatological Pathology Committee
Integrated expertise dedicated to serving every patient
At Gustave Roussy, the Skin Cancer Committee provides specialized care for melanomas, skin carcinomas, and certain rare skin tumors, as well as skin toxicity related to cancer treatments.
It brings together a multidisciplinary team of dermatologists, oncologists, surgeons, imaging and nuclear medicine specialists, radiation oncologists, interventional radiologists, pathologists, and cytopathologists.
Collaboration among these different areas of expertise allows for the development of a personalized strategy for each patient—from diagnosis through treatment and follow-up—while promoting access to innovation and clinical research.
Cancers and Conditions Treated
- Cutaneous, Mucosal, and Acrolentiginous Melanomas
- Cutaneous basal cell and squamous cell carcinomas
- Merkel cell carcinoma
- Adnexal carcinomas and other rare skin tumors
- Darier-Ferrand dermatofibrosarcoma
The Gustave Roussy Skin Cancer Committee treats patients with skin cancer, with particular expertise in advanced, metastatic, recurrent, or treatment-resistant cases.
For patients with locally advanced or metastatic skin cancer requiring rapid specialized evaluation, Gustave Roussy offers the InstaDiag Peau pathway.
This program coordinates—as much as possible within a single day—the necessary specialist consultations and tests to determine the extent of the disease and quickly establish a personalized treatment strategy.
The dermatology outpatient clinic provides a coordinated care pathway for the necessary evaluations and treatment of patients with localized skin cancers
Access to clinical trials is assessed throughout the care pathway, particularly for patients with advanced or rare diseases or those who have failed previous treatments
Expertise in the diagnosis and management of skin toxicity associated with cancer treatments, particularly immunotherapy and targeted therapies, in order to control dermatological manifestations while taking into account the requirements of oncological treatment
A multidisciplinary treatment decision
Clinical examination, histopathological analysis, imaging, and—when indicated—molecular testing are used to characterize the tumor.
The case is discussed among specialists to determine the appropriate role of surgery, medication, and radiation therapy.
The committee organizes and coordinates the various stages of the care pathway to ensure continuity between diagnosis, treatment, and follow-up.
The Committee';s Doctors
Dr. Émilie Routier
Prof. Caroline Robert
CLCC Specialist Practitioner
Dr. Djaouida Belkadi-Sadou
Dr. Céline Boutros (part-time)
University Clinical Instructor – Hospital Assistant
Dr. Violette De Savigny CLCC
Assistant Physician
Dr Pauline Ratajczyk
Dr Jacopo Uliano
Dr Macarena Rey-Cardenas
Dr Zoulikha Brahmi Adrar
CLCC Consultant Residents
Dr Bertrand Bachollet
Dr Hélène Bocquet
Dr Richard Encoua
Dr Béatrix Reynaud-Mendel
Dr Marina Thomas
Dr Jérémy Lupu
Dr Julie Blanc
Dr Jonathan Abitbol
Radiology
Dr PIERRE Thibault
Nuclear Medicine
Dr Ferad CHEHADE
DrDr Pierre Blanchard
Dr Yun Gan Tao
Dr France Nguyen Than-Van
Dr Anna Gueiderikh
Dr Kevin Veiler
Dr Kevin Darolles
Dr Andréa Cavalcanti
Dr Emilie Jaffrelo
Dr Jean-François Honart
Dr Nicolas Leymarie
Dr Antoine Moya-Plana
Heloise De-Kermadec
Leo Ouhayoun
Karlien Vrancken
Healthcare Team, Coordination, and Clinical Research
Academic Assistant
Frederika Perrier
Medical Assistants:
Valérie Pasquiet (Lead)
Mélinda Perdreau
Alexandra Palmade
Adeline Da-Cunha
Shaila Kankonde
Flore Dupuy
Fritzna Dely
Severine Roy (Project Manager)
Naima Benannoune (Project Manager)
Aurore Alvarez (Clinical Research Nurse)
Nadia Brouri (Technical Assistant)
Anna Palmier (Clinical Research Associate)
Mimi Megherbi (Clinical Research Associate)
Abdellatif Limouni (Clinical Research Associate)
Myriam Maalej-Chaari (Clinical Research Associate)
Ghofrane Sahbani (Clinical Research Associate)
Amina Zeghouani (Clinical Research Associate)
Laetitia Vie (Medical Research Assistant)
Therapeutic Innovation at the Heart of Care
Research on skin cancers aims to better understand why some tumors respond to treatment while others are resistant, to identify biomarkers that can guide treatment decisions, and to develop new strategies.
The research team led by Prof. Caroline Robert
Professor Caroline Robert leads a team focused on the mechanisms of adaptive resistance to cancer treatments. Her research focuses in particular on resistance to targeted therapies and immunotherapy in melanoma, as well as on the identification of biomarkers and new therapeutic strategies.
This close integration of clinical research, translational research, and patient care allows questions raised at the bedside to be brought into the laboratory and then evaluated through clinical trials.